2024
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imaging
2021
Adverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database